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Summary-The elrects of the anti-convulsant drug remacemide and one of its active metabolites FPL 12495 
were examined in a genetic model for generalized absence pilepsy, the WAG/Rij strain of rats. Number, mean 
and total duration of spike-wave discharges were measured following oral administration of remacemide and 
FPL 12495, together with parameters of background electroencephalographic a tivity (EEG) and spontaneous 
behaviour in the recording cage. A decrease in the number of the spike-wave discharges was found after 
remacemide administration. At the highest dose there was near total suppression of the spike-wave discharges. 
There were no im!portant effects on behaviour and on spectral content of the background EEG, suggesting 
that remacemide has little side effects. A decrease in the number of spike-wave discharges was also found 
after FPL 12495 gavage and there was a prolongation of the mean duration. Behavioural changes were only 
noticed after the highest dose. These were accompanied by changes in the spectral content and particularly 
by an increase in the amplitude of the delta and the high beta frequencies, together with a decrease in the 
spindle frequency range. FPL 12495 appeared to be more potent that remacemide in all its effects. The effects 
of mainly FPL 12495 are uncommon in the sense that so far no other investigated rug shows a decrease in 
the number together with an increase in the mean duration of the discharges. It seems that in contrast to other 
anti-epileptic drugs, FPL 12495 exerts a differential action on the two commonly distinguished mechanisms 
controlling numb’er and duration. 
Keywords--Remacemide, FPL 12495, absence epilepsy, WAG/Rij strain, genetic model, spikewave dis- 
charges, EEG, spectral analyses. 
Remacemide is a new a&i-convulsant drug. In mice and 
rats it shows a specific and potent protection in the 
maximal electroshock seizure (MES) test (Garske et al., 
1991; Palmer et al., 1992). It is also effective in suppress- 
ing audiogenic seizures and the drug inhibits NMDA 
and kainic acid induced convulsions and tonic seizures 
elicited by 4-amino pyridine (Cramer et al., 1993; Palmer 
et al., 1992). The anticonvulsant effects of remacemide 
appear to be somewhat specific for these tests since 
pentylenetetrazol, bicuculline, picrotoxin or strychnine 
induced convulsions are unaffected. The mechanism of 
remacemide is thought to be similar to phenytoin and 
other compounds which inhibit sustained repetitive 
firing of the fast Na+ channel (McLean et al., 1983). It 
has been proposed that remacemide may offer a suitable 
treatment for patients with generalized tonic-clonic and 
complex partial seizures. The desglycine metabolite of 
remacemide, FPL 12495, is an even more potent anti- 
*To whom correspondence should be addressed. 
convulsant than remacemide itself (Palmer et al., 1992) 
and is a considerably more potent antagonist of the fast 
Na+ channel and at the NMDA receptor site than 
remacemide (Harris et al., 1992). 
The molecular structures of remacemide and FPL 
12495 and their action in MES and in other models 
for convulsive epilepsy does not predict unambiguously 
the actions of these drugs against another type of 
generalized epilepsy, absence epilepsy, since various 
types of anti-convulsants react differentially in absence 
epilepsy. Drugs effective against tonic-clonic epilepsy 
such as carbamazepine and phenytoin, do not decrease 
but aggravate absence seizures. Other anti-convulsants 
such as diazepam and loreclezole reduce spike-wave 
discharges while typical anti-absence drugs such as 
ethosuximide and trimethadione decrease spike-wave 
activity (Ates et al., 1992; Micheletti et al., 1987; Peeters 
et al., 1988; Peeters, 1991). If remacemide would mimic 
the effects of carbamazepine and phenytoin, one may 
predict that spike-wave activity would be enhanced after 
remacemide. 
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Genetic models are the pertinent choice among the 
models available for human absence epilepsy (Liischer, 
1984) and such a model is the WAG/Rij strain of rats 
(Coenen et al., 1992a; van Luijtelaar and Coenen, 1986, 
1989; van Luijtelaar et al., 1991). At an age of six months 
all members of this inbred strain show the electrophysio- 
logical and behavioural manifestations of generalized 
absence epilepsy. They exhibit spontaneously occurring 
spike-wave discharges mostly during periods with a 
low level of vigilance (Drinkenburg et al., 1991; 
van Luijtelaar et al., 1991). The pharmacological profile 
of these spike-wave discharges closely resembles the 
profile of human absence epilepsy (Peeters et al., 1988). 
It will be investigated in the present experiment whether 
remacemide and FPL 12495 have effects on generalized 
absence epilepsy as shown by rats of the WAG/Rij 
strain. In order to determine whether these drugs 
have also other effects, spontaneous behaviour and 
background EEG were additionally measured. 
METHODS 
Fifty-six male WAG/Rij rats, six months of age and 
weighing between 260-382 g were used as experimental 
subjects. Animals were individually housed and had 
always access to food and water. A 12-12 hr light-dark 
cycle with bright white lights on at 20.00 hr, was main- 
tained throughout the experiment. The experiment ook 
place in the dark phase of the day, which is the time of 
day with the highest incidence of spike-wave discharges 
(van Luijtelaar and Coenen, 1988). The experimental 
room was then illuminated by a weak red light for which 
albino rats are unsensitive but which allowed us to 
observe the rats’ behaviour. 
EEG electrodes (Plastics One, MS 333/2-A) were 
implanted in the cortex under anaesthesia (Nembutal, 
60 mg/kg i.p.). They were placed in the frontal and in the 
parietal/occipital region of the cortex with coordinates A 
2.0, L 3.5 and A -6.0, L 4.0 respectively, with skull 
surface flat and bregrna zerozero. An earth electrode 
was placed in the cerebellum. The animals were allowed 
to recover for at least 10 days. Experiments were 
performed in freely moving animals singly housed in 
transparent EEG recording cages (25 x 25 x 3Ocm). 
Remacemide and FPL 12495 were supplied as 
the hydrochloride salt by Fisons Pharmaceuticals 
(Loughborough, U.K.). The compounds were dissolved 
in saline and remacemide was administered in doses of 
20, 40 and 80 mg/kg and FPL 12495 in doses of 10, 20 
and 40 mg/kg. Additionally, a control group was used 
and rats of this group received saline only. Each group 
consisted of 8 subjects. The rats were adapted to the 
recording conditions for 18 hr and a base-line EEG was 
recorded for 1 hr, starting at 10.00 hr. Then, animals 
were given remacemide, FPL 12495 or solvent in a dose 
volume of 1 ml orally and subsequently the EEG was 
recorded for 2 consecutive hours. Drugs were always 
administered at 11 .OO hr. All animals were used only once. 
The EEG signal was amplified and filtered by an 
Elema-Schonander polygraph and frequencies between 
1 and 70 Hz were allowed to pass. The EEG was stored 
in digitized form on a magneto-optical disk (DATA 
Instruments, AT-CODAS). Spike-wave discharges were 
visually scored according to criteria elaborated elsewhere 
(van Luijtelaar and Coenen, 1986). Number, mean 
and total duration of spike-wave discharges were 
determined. 
Additionally, the spectral content of the background 
EEG without spike-wave discharges, was determined 
during representative periods of passive wakefulness 
after the first hour following remacemide, FPL 12495 
or saline administration. The minimum time period that 
was analysed for each subject was 35 sec. These epochs 
were digitized with a rate of 512 samples per second. 
The power spectrum was calculated by means of a Fast 
Fourier Transformation (FFT) with a bin density of 
1 Hz, whereby the power spectrum was normalized. 
Z-scores are then obtained with a mean of zero and a 
variance of 1 in order to compensate for interindividual 
differences in amplification (Coenen and van Luijtelaar, 
1989). The content of the following EEG frequency 
bands were determined: the delta-band (l-4 Hz), the 
theta-band (6-10 Hz), the sigma-band (1 l-14 Hz), the 
beta 1 -band (15-30 Hz) and the beta 2-band ( > 30 Hz). 
Spontaneous on-going behaviour of the rats in 
their cages was observed through a window from an 
adjacent room. The duration of the following behaviour 
categories was quantified for 30 min starting 5 min after 
injection: locomotor behaviour interpreted as explora- 
tory behaviour (walking, rearing, sniffing, digging), 
automatic behaviour (grooming, eating, drinking) and 
immobile behaviour (sitting, lying and standing still) 
(Coenen and van Luijtelaar, 1989; Vanderwolf, 1969). 
Data were recorded and analysed with the Observer 
(Noldus, 199 1). 
The overall effects induced by the compounds with 
respect to number and duration of spike-wave dis- 
charges, behaviour and EEG spectral analysis, were 
statistically analyzed by means of a one-factor (doses) 
ANOVA, while post-hoc comparisons according to 
Duncan were used to test differences between groups. 
The number of degrees of freedom were always 3 and 28. 
The effects on spike-wave activity were evaluated for 
60 min periods. 
RESULTS 
Remacemide 
In Fig. l(A), the number, mean and total duration 
of the spike-wave discharges are shown before and 
after the administration of saline, 20, 40 and 80 mg/kg 
remacemide. Each bar in the histogram represents the 
values in a block of 60 min of recording. There were 
no differences between the four groups before drug 
administration. There were no differences on the number 
of spike-wave discharges between the four groups in the 
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first hour after the animals were given remacemide. 
However, there was a significant effect in the second 
hour after administration (F = 4.85, P < 0.01). The 
post-hoc test showed that the 80 mg/kg group had less 
spike-wave discharges than the saline and the 20 mg/kg 
group. Especially in the last 30 min remacemide became 
very effective: only one animal of the highest dose group 
showed just three spike-wave discharges, while the seven 
other rats had no spike-wave discharge left. Cochrans 
Q-test for dependent samples (Q = 10,36, Fg = 3, 
alpha = 0.02) confirmed that there were less animals 
with spike-wave discharges after 80 mg/kg remacemide 
than after solvent. 
The mean duration of the spike-wave discharges 
was unaltered. The total duration of the spike-wave 
discharges showed also a significant effect in the second 
hour after administration (F = 3.58, P < 0.05). The 
post-hoc test showed that the total duration of 
spike-wave discharges of the 80 mg/kg group was 
shorter than that of the 0 and 40 mg/kg groups. 
The behavioural data presented in Table 1 showed 
no significant effects. The data of the background EEG 
analyses are presented in Fig. 2(A). Although a decrease 
in the power of the spindle and beta-l frequency band 
can be inferred from this figure, there were no significant 
changes in any of the frequency bands. 
FPL 1249.5 
In Fig. l(B) the effects of FPL 12495 in doses of 
10, 20 and 40mg/kg are shown on the number, mean 
and total duration of the spike-wave discharges. There 
were no differences between the four groups prior 
to FPL 12495 administration. There was a significant 
effect on the number of spike-wave discharges in the first 
hour after drug administration (F = 6.75, P < 0.001): 
after 40mg/kg the number was decreased compared 
to 10 mg/kg and solvent and also after 20 mg/kg the 
number was decreased compared to solvent. 
Remacemide 
0 Omg/kg 
H 2Omg/kg 
01 mmg/kg 
Table 1. Effects of remacemide and FPL 12495 on behaviour. Means 
and SEMs are given 
Dose 
Remacemide 
0 w/k 
20 w/b 
40 w/k 
80 w&z 
FPL 12495 
0 w/k 
10 w/kg 
20 w/k 
Exploratory 
behaviour 
26.1 f 1.5% 
28.0 & 4.1% 
25.3 f 6.0% 
25.5 + 5.3% 
26.1 + 1.5% 32.5 + 7.2% 41.4 k 8.2% 
29.3 f 4.6% 40.0 + 8.0% 30.7 + 8.9% 
23.1 rfr 4.2% 40.3 & 6.1% 36.6 f 4.8% 
Automatic 
behaviour 
32.5 k 7.2% 
21.1 k 6.1% 
42.4 + 9.0% 
49.9 f 2.9% 
Immobile 
behaviour 
41.4 * 8.2% 
44.8 f 1.8% 
32.2 & 10.8% 
24.5 & 6.8% 
40 w/kg 40.5 + 6.3% 26.5 + 4.3% 31.2+6.4% 
The mean duration of the spike-wave discharges was 
affected by the drug in the first (F = 3.90, P < 0.05) and 
in the second (F = 9.57, P < 0.001) hour post injection. 
In the first hour the duration of 20mg/kg group was 
The total duration of the spikewave discharges was 
only reduced in the first hour (F = 4.45, P -c 0.05): the 
longer than that of the 40 and 10 mg/kg groups. In the 
40 mg/kg group differed from the 20, 10 and 0 mg/kg 
groups. 
second hour the duration was prolonged after 40 mg/kg 
compared to 20, 10 and 0 mg/kg. 
The behavioural data are presented in Table 1. The 
animals tended to show more exploratory behaviour, but 
the effects did not reach significancy. The drug had an 
effect on the number of immobile periods (F = 4.76, 
P < 0.01): the post-hoc test showed that it was enhanced 
after 40 mg/kg only. 
The data on the background EEG of FPL 12495 are 
presented in Fig. 2. A significant dose effect was found 
for the delta band (F = 3,3 1, P < 0.05): after 40 mg/kg 
group there was more delta activity than after 20 mg/kg 
or saline. There was a tendency for a dose effect in the 
theta band. In the spindle (F = 4,49, P < 0.01) and in the 
beta-2 band (F = 5,38, P < 0.01) significant dose effects 
could be demonstrated: the amplitude was smaller in the 
FPL 12495 
Cl OmwW 
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El 20mg/kg 
3.01 _ 
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r o.40 
-1.0 ! - -0.60 
delta theta spindle beta-l beta2 
-1.0 A 
delta theta spindle 
- -0.60 
beta- 1 beta2 
Fig. 2. (A) The effects of saline and three doses of remacemide on the background EEG. (B) The effects of saline 
and three doses of FPL 12495 on the background EEG. Means and standard errors are depicted. 
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spindle band after 40 mg/kg compared to saline or to 
10 mg/kg, but larger in the beta-2 band after 40 mg/kg 
compared to saline. 
DISCUSSION 
Although there are some clear differences between 
the two compounds with respect to time of onset and 
potency, the present data show that both remacemide 
and FPL 12495 decrease the number of spike-wave 
discharges in this genetic model for generalized absence 
epilepsy. The decrease in the number of spike-wave 
discharges after specifically remacemide application was 
found however in the highest dose and in the second 
hour only. This late onset is probably due to the oral 
administration of remacemide and to the fact that this 
drug has to be metabolized in order to become active and 
to suppress spike-wave discharges. Remacemide is 
metabolized into FPL 12495 and at its turn FPL 12495 
is further metabolized into FPL 14465 and FPL 14330. 
In fact remacemide has nine identified and five potential 
metabolites (Palmer et al., 1992). Both metabolites FPL 
14465 and FPL 14330 can be found in cerebrospinal f uid 
and in the plasma (Palmer et al., 1992) in rats but it is 
unknown whether these and other metabolites uppress 
spike-wave discharges. The decrease in epileptic activity 
was also evident from the decrease in the total duration 
of spike-wave discharges, again after the highest dose 
only and this was also particularly striking 90-120 min 
after administration. At that time only one single animal 
showed spike-wave discharges and only three in num- 
ber: i.e. a mean of less than 0.5 spike-wave discharge 
compared to habitual twenty under base-line conditions. 
Since the plasma concentration after oral administration 
of remacemide peaks at 30 min and declines to approxi- 
mately a quarter of that value in 2 hr, it seems likely 
that the firm suppression of the number of spike-wave 
discharges after 90-l 20 min can be more likely 
attributed to either a combined action of remacemide 
and active metabolites rather than to remacemide itself. 
The duration of the action of the active metabolites 
exceeded the 2 hr recording period and therefore it 
remains unclear how long remacemide or their metab- 
olites suppress spike-wa.ve discharges. 
FPL 12495 is more potent than remacemide in 
decreasing the number of spike-wave discharges and 
acts also faster than remacemide. FPL 12495 reaches its 
maximum plasma value after 30 min and remains con- 
stant for several hours (F’almer et al., 1992). Surprisingly, 
FPL 12495 increases the mean duration of spike-wave 
discharges. It is of interest hat the effects on number and 
on mean duration of spilte-wave discharges dissociate in 
two ways, firstly on time and secondly on direction. 
Firstly, the effects on th,e number are immediately pre- 
sent and stay limited to the first hour, while the effects 
on the mean duration tend to be present in the first hour 
and are larger in the second hour. This latter finding 
suggests that the effects on duration are due to a 
combined action of FPL 12495 and one or more of its 
active metabolites. Another possibility is that FPL 12495 
is racemic and that its differential effects on time 
might be related to varying effects of the two isomers. 
Secondly, there is also a dissociation with respect o the 
direction of the induced changes in the anti-epileptic 
activity of FPL 12495. This compound suppresses the 
number of spikewave discharges but it prolongs their 
mean duration; a decrease in the number together with 
an increase in the mean duration of the spike-wave 
discharges is striking and uncommon. Until now we and 
others have evaluated specific anti-absence drugs, anti- 
convulsants, broad spectrum anti-epileptics (Ates et al., 
1992; Coenen and van Luijtelaar, 1989; Micheletti et al., 
1987; Peeters et al., 1988; van Luijtelaar and Coenen, 
1989), p-carbolines (Coenen et al., 1989, 1992b), 
quisqualate, kainate and NMDA receptor agonists and 
antagonists (Frey and Voits, 1991; Peeters et al., 1989; 
Peeters, 1991) GABA-ergic compounds (Micheletti 
et al., 1985; Peeters et al., 1989a), morphine-like 
analgesics (Frey and Voits, 1991) and opiates (Lason 
et al., 1994), dopaminergic agents (Buzsaki et al., 1990; 
Warter et al., 1988) central anticholinergics (Frey and 
Voits, 199 1) and psychotropic and alpha-adrenergic 
agents (Kleinlogel, 1995; Vanderwolf, 1969). Although 
not all authors distinguished between the number and 
the mean duration of the spike-wave discharges, it was 
not remarked that any of these compounds decreased the 
number of spike-wave discharges associated with an 
increase of its mean duration. This means that the 
present data are rather uncommon in the sense that they 
indicate that a single compound and probably one of its 
metabolites may exert effects on number and mean 
duration in opposite ways. 
It has to be remarked that the drug mechanisms 
involved in protection against spike-wave discharges 
might be quite different from those involved in protect- 
ing against maximal electroshock seizures. Phenytoin 
and carbamazepine are very effective in the maximal 
electroshock test, but they increase the numbers of 
spike-wave discharges (Peeters et al., 1988; van Luijte- 
laar and Coenen, 1989). Remacemide and FPL 12945 
reduce the number of spike-wave discharges and they 
are effective in the maximal electroshock test (Palmer 
et al., 1992; Stagnitto et al., 1990). It seems however, that 
remacemide is more potent in the electroshock test at 
which an ED50 as low as 21.4 mg/kg was noticed. Here 
only 80 mg/kg was effective. 
The level of vigilance and the number of spike-wave 
discharges have an intimate relationship. Few spike- 
wave discharges can be expected during periods of high 
vigilance and active behaviour and vice versa (Coenen 
et al., 1992; Drinkenberg et al., 1991; van Luijtelaar 
et al., 1991). The present data show that the decrease in 
the number of spike-wave discharges after the highest 
dose of remacemide is not accompanied by clear changes 
in motor activity and by changes in the background 
EEG. 
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The highest dose of FPL 12495 induced a tendency 
for more locomotor activity while the number of 
immobile periods was enhanced with shorter durations, 
implying some behavioural activation. Enhanced ac- 
tivity prevents the occurrence of spike-wave discharges 
and it cannot be excluded that the decrease in the 
number of spike-wave discharges is secondary to the 
increase in locomotor activity. However, the behavioural 
changes occurred only after the highest dose of FPL 
12495 while the effects on the number of spike-wave 
discharges were already present after the middle dose. 
This suggests that the effects of FPL 12495 on 
spike-wave discharges are more due to its anti-epileptic 
action and not to its mild behavioural changes. 
The spectral analysis of the background EEG did 
not reveal significant changes after remacemide. This 
suggests that remacemide has no effects on the back- 
ground EEG activity as so many psychoactive drugs 
including anti-epileptics (Duncan, 1987; Krijzer et al., 
1993). The highest dose of FPL 12495 induced changes 
in the spectral content: an increase in the delta and in the 
high beta range and a decrease in the spindle band. 
Krijzer et al. (1993) observed a power increase in the 
35-100 Hz and a power decrease from 15 to 25 Hz in 
the frequency spectrum of some psychostimulant drugs. 
The effects on the spectral content might be related to a 
yet unknown common property of FPL 12495 and these 
psychostimulant drugs, perhaps a high affinity for the 
non-competitive NMDA receptor (Harris et al., 1992). 
It can be concluded that remacemide has some anti- 
absence activity in this model and that its active 
metabolite, FPL 12495, also reduces absence activity in 
spite of a tendency to increase the mean duration of 
spike-wave discharges. FPL 12495 seems more potent 
than remacemide in reducing the number of spike-wave 
discharges. The combination of the decrease in number 
and increase in mean duration, in particular for FPL 
12495 is rather uncommon and offers a way to separate 
the mechanisms responsible for the onset and the dur- 
ation of spikewave discharges. FPL 12495 has effects on 
behaviour and an EEG profile with some similarity to 
that of psychostimulant drugs. Remacemide has no large 
effects on behaviour and does not affect the background 
EEG and it should be tried in intractable types of 
absence epilepsy. 
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